Login to Your Account


Neighborhood watch: Gene maps get 'Syros,' draw $53M series B

By Randy Osborne
Staff Writer

Monday, October 27, 2014
Mapper of gene-control pathways directly in human disease tissue, Syros Pharmaceuticals Inc. plans to use $53 million in series B cash to advance cancer programs toward the clinic and widen the gene-control product engine into new therapeutic areas.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription